Efficacy of surface disinfectant cleaners against emerging highly resistant gram-negative bacteria

Mirja Reichel1, Anastasija Schlicht2, Christiane Ostermeyer3 and Günter Kampf1,4*

Abstract

Background: Worldwide, the emergence of multidrug-resistant gram-negative bacteria is a clinical problem. Surface disinfectant cleaners (SDCs) that are effective against these bacteria are needed for use in high risk areas around patients and on multi-touch surfaces. We determined the efficacy of several SDCs against clinically relevant bacterial species with and without common types of multidrug resistance.

Methods: Bacteria species used were ATCC strains; clinical isolates classified as antibiotic-susceptible; and multi-resistant clinical isolates from Klebsiella oxytoca, Klebsiella pneumoniae, and Serratia marcescens (all OXA-48 and KPC-2); Acinetobacter baumannii (OXA-23); Pseudomonas aeruginosa (VIM-1); and Achromobacter xylosoxidans (ATCC strain). Experiments were carried out according to EN 13727:2012 in quadruplicate under dirty conditions. The five evaluated SDCs were based on alcohol and an amphoteric substance (AAS), an oxygen-releaser (OR), surface-activesubstances (SAS), or surface-active-substances plus aldehydes (SASA; two formulations). Bactericidal concentrations of SDCs were determined at two different contact times. Efficacy was defined as a log10 ≥ 5 reduction in bacterial cell count.

Results: SDCs based on AAS, OR, and SAS were effective against all six species irrespective of the degree of multi-resistance. The SASA formulations were effective against the bacteria irrespective of degree of multi-resistance except for one of the four P. aeruginosa isolates (VIM-1). We found no general correlation between SDC efficacy and degree of antibiotic resistance.

Conclusions: SDCs were generally effective against gram-negative bacteria with and without multidrug resistance. SDCs are therefore suitable for surface disinfection in the immediate proximity of patients. Single bacterial isolates, however, might have reduced susceptibility to selected biocidal agents.

Keywords: Surface disinfection cleaner, Gram-negative bacteria, Multidrug resistance, Pan-drug resistance

Background

Healthcare-associated infections, especially with multidrug-resistant gram-negative bacteria (MRGN) are an emerging problem in infection control [1]. MRGN are responsible for serious infections and have a significant impact on morbidity and mortality [2]. The spread of these organisms as well as the spread of resistance genes is an emerging public health issue [3,4]. Only limited therapeutic options are available and finding effective and suitable antibiotic drugs to treat infections can be difficult.

The main influence on the development of antibiotic drug resistance is antibiotic use, both the total amount of antibiotics used and the distribution of antimicrobial classes. For example, data from Germany show that despite a stable total amount of antibiotics used between 2001 and 2008, carbapenem use doubled. This was associated with an increase in carbapenem-resistant Klebsiella pneumoniae, carbapenemase-producing bacteria and imipenem-resistant Acinetobacter baumannii [5].

Once resistance is established, MRGN spread, especially with global travel [6]. Reports of MRGN outbreaks are abundant in the literature [7,8]. Recent data from Russia show that extensively drug-resistant Pseudomonas aeruginosa spread rapidly throughout Russia and into Belarus and Kazakhstan [9]. The damage of MRGN must be limited by preventing transmission.
This strategy is reflected in a 2012 recommendation from the Commission for Hospital Hygiene and Infectious Disease Prevention (KRINKO) at the Robert Koch-Institute in Germany for handling patients infected or colonized with MRGN. In 2014, the ESCMID also published a guideline on infection control measures MRGN in hospitalized patients [10]. In contrast to the more epidemiologically based approach of Magiorakos et al. [11], the German recommendation focused on the clinical relevance of the resistance pattern. For individual pathogens, the most important antibiotics for treating severe infections were determined by resistance pattern (acylureidopenicillins, third-generation and fourth-generation cephalosporins, carbapenems, and fluoroquinolones). According to the KRINKO definition, 3MRGN are resistant to three of these four classes; 4MRGN are gram-negative microorganisms resistant to all four classes and include pan-resistant microorganisms. The recent ESCMID guideline does not distinguish different resistance patterns within MRGN [10].

A key factor in prevention of MRGN infections is the consequent implementation and compliance with effective hygiene measures [12,13] which is also described in the ESCMID guideline [10]. Targeted surface disinfection is a major measure of standard infection control. The surface disinfectants must be effective against the targeted pathogens. Surfaces near patients and high-touch surfaces must be effectively disinfected.

Surface disinfectant cleaners (SDCs) that are often used for this purpose and can be used in the immediate proximity of patients are usually based on surface-active ingredients such as quaternary ammonium compounds (QACs). Some data indicate that adaptation or resistance to QACs can develop and QACs have greater activity against gram-positive bacteria compared to gram-negative bacteria [14,15]. Therefore, we determined the efficacy of several common SDCs against clinically relevant bacterial species with and without common types of multidrug resistance.

Methods

Test products

Five SDCs were tested at the concentration which is listed to be bactericidal using standard test bacteria (Table 1). Bacillol 30 foam, based on alcohols and an amphoteric substance (AAS) was tested undiluted for 30 and 60 s; Mikrobac forte, based on surface-active substances (SAS) was tested at 0.5% for 30 and 60 min; Dismozon plus, based on an oxygen-releaser (OR), was tested at 0.4% for 30 and 60 min; Kohrsolin extra, based on surface-active substances and an aldehyde (SASA1), was tested at 0.25% for 30 and 60 min; and Kohrsolin FF, based on surface-active substances and an aldehyde (SASA2), was tested at 0.5% for 30 and 60 min. All SDCs were manufactured by Bode Chemie GmbH, Hamburg, Germany. Products were blinded for the investigation.

Tested bacterial species

Bacterial species were selected because they are specifically mentioned in the German and the European recommendation (K. pneumoniae, P. aeruginosa, A. baumannii) [10,13], or because they have been described before to be potentially less susceptible to selected biocidal agents of SDCs (Serratia marcescens, Klebsiella oxytoca, Achromobacter xylosidans) [16-18]. They were used as: S. marcescens (ATCC 14756 and four clinical isolates: antibiotic-susceptible (“0MRGN”), 3MRGN, 4MRGN OXA-48 and 4MRGN KPC-2); K. pneumoniae (ATCC 10031 and four clinical isolates: antibiotic-susceptible, 3MRGN, 4MRGN OXA-48 and 4MRGN KPC-2); K. oxytoca (ATCC 700324 and four clinical isolates: antibiotic-susceptible, 3MRGN, 4MRGN OXA-48 and 4MRGN KPC-2); P. aeruginosa (ATCC 15442 and three clinical isolates: antibiotic-susceptible, 3MRGN and 4MRGN VIM-1); A. baumannii (ATCC 19606 and two clinical isolates: antibiotic-susceptible and 4MRGN OXA-23); and A. xylosidans (ATCC 27061). The eight 4MRGN isolates were from the National Reference Laboratory for multidrug-resistant gram-negative bacteria, Ruhr University Bochum, Germany. The five antibiotic-susceptible isolates and four 3MRGN isolates were kindly provided by the Laboratory Fenner, Hamburg, Germany.

Determination of bactericidal activity

All experiments were carried out at Labor L + S AG, Bad Bocklet, Germany, according to EN13727:2012 which is
the suspension test to determine the spectrum of bactericidal activity of disinfectants used in human medicine [19]. All tested products are used as disinfectant cleaners so dirty conditions with an interfering substance of 0.3% bovine albumin and 0.3% sheep erythrocytes were used. Each experiment was carried out in quadruplicate on different test days and by different investigators.

From a second subculture on agar plates, a test suspension was adjusted to 1.5–5.0 × 10^8 colony forming units (cfu) per ml. To 1 ml test suspension, 1 ml interfering substance with 3% bovine albumin and 3% sheep erythrocytes was added and mixed. The mixture was placed in a water bath (20 ± 1°C) for 2 min and 8 ml of tested product was added. After mixing, the tube was placed in the water bath for the indicated time, mixed again before the end of incubation, and 1 ml added to a tube with 8 ml neutralizing broth (3.0% Tween 80, 3.0% saponin, 0.1% histidine, 0.1% cysteine in tryptic soy broth) and 1 ml water. After mixing, the tube was placed in the water bath for 5 min (for 30 or 60 min contact times) or 10 s (for 30 or 60 s contact times). Neutralizing agents were validated for all SDCs using all species as ATCC strains. At the end of neutralization, the sample was mixed, and diluted 1:10 with neutralizing broth. 0.5 ml of sample without dilution was plated in quadruplicate and 0.5 ml of each dilution step in duplicate on TSA containing neutralizers (Biomérieux, Nürtingen, Germany and heipha Dr. Müller GmbH, Eppelheim, Germany). Plates were incubated at 37 ± 1°C for 48 h and colonies per plate counted. All plates from a step in quadruplicate and 0.5 ml of each dilution with neutralizing broth. 0.5 ml of sample without dilution was plated in quadruplicate and 0.5 ml of each dilution step in duplicate on TSA containing neutralizers (Biomérieux, Nürtingen, Germany and heipha Dr. Müller GmbH, Eppelheim, Germany). Plates were incubated at 37 ± 1°C for 48 h and colonies per plate counted. All plates from a dilution step with <330 cfu were used to calculate the number of cfu/mL in a sample of disinfectant, test organism, and interfering substance. Data were converted to log_{10} scale. Bacterial reduction was calculated as viable colonies before exposure to a disinfectant minus viable colonies after exposure. The EN13727 requirement for bactericidal activity is a log_{10} reduction ≥5 within the chosen contact time. Controls for experimental conditions and neutralizer, and dilution neutralization validation were carried out according to EN 13727.

**Data presentation**

When all four experiments per product, test organism and time indicated a log_{10} reduction ≥5, the lowest log_{10} reduction of the four results is presented. If the four experiments indicated a log_{10} reduction <5, mean and standard deviation were calculated. A general correlation between efficacy of a SDC and bacterial antibiotic-resistance status was assumed if a SDC was less effective against a 4MRGN compared to a 3MRGN and if it was at the same time less effective against a 3MRGN compared to a 0MRGN.

**Results**

All AAS, SAS, and OR products were effective (≥5 log_{10} reduction) against all tested species, the ATCC strains and the clinical isolates with and without multidrug-resistance (Tables 2 and 3). No efficacy gap was observed among the products against the tested gram-negative strains. SAS products were also comprehensively effective against S. marcescens, K. pneumonia, K. oxytoca, A. baumannii and A. xylosidans, both ATCC strains and clinical isolates with and without multidrug-resistance. They were also effective against *P. aeruginosa* ATCC 15442, 0MRGN and 3MRGN but were not sufficiently effective against 4MRGN VIM-1 with a mean log_{10} reduction of 1.54–3.45 (Table 3). No general correlation was seen between efficacy of all five SDC and bacterial antibiotic-resistance status with five of six bacterial species (25 possible correlations). It was also not seen for three SDCs with *P. aeruginosa* (3 possible correlations). It was partly seen for 2 SAS products with *P. aeruginosa* but only for the comparison of 4MRGN versus 3MRGN and not for the comparison 3MRGN versus 0MRGN.

**Discussion**

All SDCs containing SAS were generally effective against MRGN. Literature reports on SAS efficacy are conflicting. Some studies found that SAS are not sufficiently effective against gram-negative bacteria or that efficacy is lower against gram-negative than against gram-positive bacteria [14,20-23]. Other studies found that SAS are effective [24,25]. Outbreaks of contaminated SAS disinfectant solutions have been reported [26-28]. Some strains, particularly biofilm-forming species, survive or even multiply in SAS disinfectants at concentrations at which they are normally used and this can result in infections such as septicemia [29,30]. Our results did not support the hypothesis that SAS-containing products are insufficiently effective against gram-negative bacteria. We found that SAS products were highly effective against multiple clinically relevant gram-negative microorganisms.

The link between lower susceptibility to SAS and antibiotic resistance is not conclusively established [31,32]. No resistance breakpoints have been defined for biocides so defining resistance to these compounds is difficult. In addition, reversible adaptations to an active ingredient versus stable resistance must be distinguished [33,34]. SAS are used for multiple applications, e.g., in the cosmetic, pharmaceutical, and food industries. Adaptation and resistance have been shown for different species. For gram-negative bacteria, cross-resistance to different antibiotics and to different types of SAS, and selection for antibiotic-resistant strains has been found [35,36]. Antibiotic resistance and resistance to biocides can have the same molecular mechanisms, although biocides generally show a broader activity because their mode of action is nonspecific [37-39]. The association between antibiotic resistance and biocide resistance seen in gram-negative bacteria can be explained by a link between the genes for
**Table 2 Log₁₀-reduction of cell counts by five surface disinfectant cleaners against emerging multidrug-resistant enterobacteriaceae and corresponding ATCC strains**

| Species                  | Isolate/strain | Product (concentration) | Contact time        | Log₁₀-reduction |
|--------------------------|----------------|-------------------------|---------------------|-----------------|
| *Serratia marcescens*    | ATCC 14756     | AAS (undiluted)         | 30 and 60 s         | > 5.47          |
|                          |                | SAS (0.5%)              | 30 and 60 min       |                 |
|                          |                | OR (0.4%)               |                     |                 |
|                          |                | SASA1 (0.25%)           |                     |                 |
|                          |                | SASA2 (0.5%)            |                     |                 |
|                          | 0MRGN          | AAS (undiluted)         | 30 and 60 s         | > 5.37          |
|                          |                | SAS (0.5%)              | 30 and 60 min       |                 |
|                          |                | OR (0.4%)               |                     |                 |
|                          |                | SASA1 (0.25%)           |                     |                 |
|                          |                | SASA2 (0.5%)            |                     |                 |
|                          | 3MRGN          | AAS (undiluted)         | 30 and 60 s         | > 5.17          |
|                          |                | SAS (0.5%)              | 30 and 60 min       |                 |
|                          |                | OR (0.4%)               |                     |                 |
|                          |                | SASA1 (0.25%)           |                     |                 |
|                          |                | SASA2 (0.5%)            |                     |                 |
|                          | 4MRGN          | AAS (undiluted)         | 30 and 60 s         | > 5.14          |
|                          |                | SAS (0.5%)              | 30 and 60 min       |                 |
|                          |                | OR (0.4%)               |                     |                 |
|                          |                | SASA1 (0.25%)           |                     |                 |
|                          |                | SASA2 (0.5%)            |                     |                 |
| *Klebsiella pneumoniae*  | ATCC 10031     | AAS (undiluted)         | 30 and 60 s         | > 5.34          |
|                          |                | SAS (0.5%)              | 30 and 60 min       |                 |
|                          |                | OR (0.4%)               |                     |                 |
|                          |                | SASA1 (0.25%)           |                     |                 |
|                          |                | SASA2 (0.5%)            |                     |                 |
|                          | 0MRGN          | AAS (undiluted)         | 30 and 60 s         | > 5.08          |
|                          |                | SAS (0.5%)              | 30 and 60 min       |                 |
|                          |                | OR (0.4%)               |                     |                 |
|                          |                | SASA1 (0.25%)           |                     |                 |
|                          |                | SASA2 (0.5%)            |                     |                 |
|                          | 3MRGN          | AAS (undiluted)         | 30 and 60 s         | > 5.09          |
|                          |                | SAS (0.5%)              | 30 and 60 min       |                 |
|                          |                | OR (0.4%)               |                     |                 |
|                          |                | SASA1 (0.25%)           |                     |                 |
|                          |                | SASA2 (0.5%)            |                     |                 |
|                          | 4MRGN OXA-48   | AAS (undiluted)         | 30 and 60 s         | > 5.38          |
|                          |                | SAS (0.5%)              | 30 and 60 min       |                 |
|                          |                | OR (0.4%)               |                     |                 |
|                          |                | SASA1 (0.25%)           |                     |                 |
|                          |                | SASA2 (0.5%)            |                     |                 |
both resistance mechanisms [40]. Of note, studies on resistance are often carried out with concentrations of surface disinfectants lower than what is normally used. To avoid concentrations of SDC that are sublethal to bacteria, recommended concentrations and contact times must be known and used.

We did not find a general correlation between antibiotic-resistance patterns and susceptibility to SAS-containing products, consistent with earlier reports [41]. Only a single 4MRGN P. aeruginosa isolate had lower susceptibility to the two aldehyde-containing SAS products. Nonetheless, the products were highly effective against three other P. aeruginosa isolates indicating that reduced susceptibility was strain-specific. Individual clinical strains can show reduced susceptibility to aldehyde [42,43]; especially for some P. aeruginosa strains, published data are available on the lower efficacy of aldehyde-containing products [44-46]. We do not know the underlying mechanism of the reduced susceptibility of the isolate in our study. However, determining the molecular mechanism of the lowered susceptibility would be interesting and help to better understand our findings.

We found that products based on an OR compound or AAS were highly effective. A few studies with alcohol-
## Table 3 Log$_{10}$ reduction of cells counts by five surface disinfectant cleaners against emerging multidrug-resistant non-fermenting bacteria and corresponding ATCC strains

| Species                      | Isolate/strain | Product (concentration) | Contact time | Log$_{10}$-reduction |
|------------------------------|----------------|-------------------------|--------------|----------------------|
| **Pseudomonas aeruginosa**   | ATCC 15442     | AAS (undiluted)         | 30 and 60 s  | >5.28                |
|                              |                | SAS (0.5%)              | 30 and 60 s  |                      |
|                              |                | OR (0.4%)               |              |                      |
|                              |                | SASA1 (0.25%)           |              |                      |
|                              |                | SASA2 (0.5%)            |              |                      |
| 0MRGN                        | AAS (undiluted) | 30 and 60 s            | >5.14        |                      |
|                              | SAS (0.5%)     | 30 and 60 min          |              |                      |
|                              | OR (0.4%)     |                        |              |                      |
|                              | SASA1 (0.25%) |                        |              |                      |
|                              | SASA2 (0.5%)  |                        |              |                      |
| 3MRGN                        | AAS (undiluted) | 30 and 60 s            | >5.06        |                      |
|                              | SAS (0.5%)     | 30 and 60 min          |              |                      |
|                              | OR (0.4%)     |                        |              |                      |
|                              | SASA1 (0.25%) |                        |              |                      |
|                              | SASA2 (0.5%)  |                        |              |                      |
| 4MRGN VM-1                   | AAS (undiluted) | 30 s and 60 s         | >5.45        |                      |
|                              | SAS (0.5%)     | 30 and 60 min          |              |                      |
|                              | OR (0.4%)     |                        |              |                      |
|                              | SASA1 (0.25%) |                        | 30 min       | 1.54 ± 0.91          |
|                              |                |                        | 60 min       | 1.76 ± 0.94          |
|                              | SASA2 (0.5%)  |                        | 30 min       | 3.04 ± 0.73          |
|                              |                |                        | 60 min       | 3.45 ± 0.55          |
| **Acinetobacter baumannii**  | ATCC 19606     | AAS (undiluted)         | 30 and 60 s  | >5.20                |
|                              |                | SAS (0.5%)              | 30 and 60 min|                      |
|                              |                | OR (0.4%)               |              |                      |
|                              |                | SASA1 (0.25%)           |              |                      |
|                              |                | SASA2 (0.5%)            |              |                      |
| 0MRGN                        | AAS (undiluted) | 30 and 60 s            | >5.09        |                      |
|                              | SAS (0.5%)     | 30 and 60 min          |              |                      |
|                              | OR (0.4%)     |                        |              |                      |
|                              | SASA1 (0.25%) |                        |              |                      |
|                              | SASA2 (0.5%)  |                        |              |                      |
| 4MRGN OXA-23                 | AAS (undiluted) | 30 and 60 s            | >5.14        |                      |
|                              | SAS (0.5%)     | 30 and 60 min          |              |                      |
|                              | OR (0.4%)     |                        |              |                      |
|                              | SASA1 (0.25%) |                        |              |                      |
|                              | SASA2 (0.5%)  |                        |              |                      |
| **Achromobacter xylosidans** | ATCC 27061     | AAS (undiluted)         | 30 and 60 s  | >5.13                |
|                              |                | SAS (0.5%)              | 30 and 60 min|                      |
|                              |                | OR (0.4%)               |              |                      |
|                              |                | SASA1 (0.25%)           |              |                      |
|                              |                | SASA2 (0.5%)            |              |                      |

Experiments were carried out in quadruplicate under dirty conditions; lowest log$_{10}$ reduction values or mean and standard deviation are shown.
based hand rubs revealed that they are effective against multidrug-resistant bacterial isolates including multidrug-resistant *Mycobacterium tuberculosis* [47,48]. No studies have found that OR compounds used on surfaces are not fully effective against bacteria. Both OR and AAS are considered to have a nonspecific mechanism of action [49] and are volatile (alcohol) or degradable (OR compounds). Therefore, acquired bacterial resistance to OR or AAS products is very unlikely.

A limitation of this study for clinical practice is experiments were carried out with bacteria in suspension and not under practical conditions. Suspension tests are the first-choice method for studying the spectrum of antimicrobial activity of disinfectants [50]. Testing the effectiveness of the formulations under practical conditions would also be interesting. In Europe, a test method is currently being developed to determine both the efficacy of surface disinfectants on a contaminated test field and the potential to spread of bacteria by wiping to non-contaminated surfaces [51]. Future research could determine the effectiveness of SDCs tested under practical conditions.

Recent data from Germany show that the percentage of MRGN in a hospital exceeded nosocomial infection rates by MRSA and VRE (8% vs. 2% for MRSA and VRE) [52]. The main reason is that once multidrug-resistance is established, the spread of resistant strains is inevitable. Currently, no effective sanitation methods exist against MRGN carriers. Even with contact precautions in patient care, standard hygiene measures are still essential for preventing of transmission of MRGN. Targeted surface cleaning and disinfection is an element of standard hygiene in hospitals.

**Conclusions**

Our data showed that SDCs with different active ingredients were generally effective against a variety of emerging multidrug-resistant bacterial species.

**Competing interests**

MR, CO and GK are employed by BODE Chemie GmbH, Hamburg, Germany.

**Authors’ contribution**

MR and GK designed the study. AS was responsible for the performing all experiments. AS and MR analyzed the data. MR and GK drafted the manuscript; AS and CO critically revised the manuscript. All authors approved the final version of the manuscript.

**Funding**

This study was funded by BODE Chemie GmbH, Hamburg, Germany.

**Author details**

1. Bode Science Center, Bode Chemie GmbH, Melanchthonstr. 27, 22525 Hamburg, Germany. 2. Labor L + S AG, Mangelfeld 4, 5, 6, 97708, Bad Bocklet-Großenbrach, Germany. 3. Microbiology, Bode Chemie GmbH, Melanchthonstr. 27, 22525 Hamburg, Germany. 4. Institute for Hygiene and Umweltmedizin, Ernst-Moritz-Arndt Universität Greifswald, Walther-Rathenau-Straße 49a, 17475 Greifswald, Germany.

**Received:** 21 February 2014 **Accepted:** 21 May 2014

**Published:** 28 May 2014

**References**

1. Wellington EM, Boxall AB, Cross P, Fell EJ, Gaze WH, Hawkey PM, Johnson-Rollings AS, Jones DL, Lee NM, Otten W, Thomas GM, Williams AP. The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteria. *Lancet Infect Dis* 2013, 13(2):155–165.

2. Vonberg RP, Wolter A, Chaberny IF, Kola A, Ziesing S, Suerbaum S, Gastmeier P. Epidemiology of multi-drug-resistant gram-negative bacteria: data from an university hospital over a 36-month period. *Int J Hyg Environ Health* 2008, 211(3–4):251–257.

3. Savard P, Carroll KC, Wilson LE, Perl TM. The challenges of carbapenemase-producing enterobacteriaceae and infection prevention: protecting patients in the chaos. *Infect Control Hosp Epidemiol* 2013, 34(7):730–739.

4. Magiorakos AP, Suetens C, Monnet DL, Gagliotti C, Heuer OE. The rise of carbapenem resistance in Europe: just the tip of the iceberg? *Antimicrobial Resistance and Infection Control* 2013, 2:166.

5. Meyer E, Schwab F, Schroten-Boersch B, Gastmeier P. Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. *Crit Care* 2010, 14(3):R113.

6. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhury U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Mahajan S, Murshtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sherden E, Thirunavayi MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis* 2010, 10(9):597–602.

7. Tamma PD, Piel T, Sonnevend A, Perl TM, Milestone AM. An outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit. *Infect Control Hosp Epidemiol* 2012, 33(6):631–634.

8. Mosqueda N, Espinal P, Cosgaya C, Viota S, Plasencia V, Lerma FA, Montero M, Gomez J, Horcajada JP, Vila J, Roca I. Globally expanding carbapenemase finally bursts in Spain: Nosocomial outbreak of Acinetobacter baumanii producing a plasmid-encoded OXA-23 in Barcelona, Spain. *Antimicrob Agents Chemother* 2013, 57(10):5155–5157.

9. Edelstein MW, Skinevova EN, Shevchenko ON, D’Souza JW, Tapalski DV, Aszov IS, Sukhorukova MV, Pavlukov RA, Kozlov RS, Toleman MA, Walsh TR. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. *Lancet Infect Dis* 2013, 13(10):867–876.

10. Taccoroni EL, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, Kahnrieter G, Pan A, Petrosillo N, Rodriguez-Bano J, Singh N, Venditti M, Yokoe DS, Cookson B. ESzCMD guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. *Clin Microbiol Infect* 2014, 20(Suppl 1):1–55.

11. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stirling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012, 18(3):268–281.

12. Anonym. Minnesota department of health recommendations for the management of carbapenem-resistant enterobacteriaceae in long-term care facilities. In *Infectious Disease Epidemiology P&Co*, vol. St. Paul, MN, USA: Minnesota Department of Health; 2012.

13. Anonym. Hygienemaßnahmen bei Infektionen oder Besiedelung mit multiresistenten gramnegativen Stäbchen. *Bundesgesundheitsblatt* 2012, 55(10):1311–1354.

14. Boek SS. Disinfection, sterilization, and preservation. 4th edition. Philadelphia: Lea & Febiger; 1991.

15. Boyle JM, Pittet D. Guideline for hand hygiene in health-care settings. Recommendations of the healthcare infection control practices advisory committee and the HICPAC/SHEA/APIC/IDSA hand hygiene task force. *MMWR - Morbidity & Mortality Weekly Report* 2002, 51:1–45.

16. Gebel J, Sonntag HG, Werner HP, Vacata V, Enner M, Kistemann T. The higher diagnostic resistance of nosocomial isolates of Klebsiella
of Klebsiella oxytoca: how reliable are indicator organisms in disinfectant testing? Journal of Hospital Infection 2002, 50(4):309–311.

17. Kampf G, Degenhardt S, Lackner S, Jesse K, von Baum H, Ostermeyer C: Poorly processed reusable surface disinfection tissue dispensers may be a source of infection. BMC Infect Dis 2014, 14:37.

18. Gortner L, Borkhardt A, Reiss I, Räden H, Daschner F: Higher disinfectant resistance of nosocomial isolates of Klebsiella oxytoca: indicator organisms in disinfectant testing are not reliable. Journal of Hospital Infection 2003, 53(2):153–155.

19. EN 13727:2012: Chemical disinfectants and antiseptics. Quantitative suspension test for the evaluation of bactericidal activity in the medical area. Test method and requirements (phase 2, step 1). Brussels: CEN - Comité Européen de Normalisation; 2012.

20. Namba Y, Suzuki A, Takeshima N, Kato N: Comparative study of bactericidal activities of six different disinfectants. Nagoya J Med Sci 1985, 47(10):112–112.

21. Fazlara A, Ehteltal M: The disinfectant effects of benzalkonium chloride on some important foodborne pathogens. American-Eurasian Journal of Agricultural & Environmental Science 2012, 12(1):23–29.

22. McDonnell G, Russell AD: Antiseptics and disinfectants: action, activity, and resistance. Clin Microbiol Rev 1999, 12(1):147–179.

23. Ali Y, Kimura A, Coffey MJ, Tyle P: Antibacterial efficacy of disinfectants against some gram-negative bacteria. Cent Eur J Public Health 2002, 10(3):104–106.

24. Weber Dj, Rutala WA: Use of germicides in the home and the healthcare setting: is there a relationship between germicide use and antibiotic resistance? Infect Control Hosp Epidemiol 2006, 27(10):1107–1119.

25. Tschudin-Sutter S, Frei R, Kampf G, Tamm M, Pflimlin E, Battegay M, Widmer AF: Emergence of glutaraldehyde-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2011, 32(12):1173–1178.

26. Tschudin-Sutter S, Ostermeyer C, Tschudin-Sutter S, Widmer AF: Resistance or adaptation? How susceptible is a ‘glutaraldehyde-resistant’ Pseudomonas aeruginosa isolate in the absence of selection pressure? J Hosp Infect 2013, 84(4):316–318.

27. Kauflers PM, Marquardt A: Demonstration of formaldehyde dehydrogenase activity in formaldehyde-resistant Enterobacteriaceae. FEMS Microbiol Lett 1991, 84(2–3):335–338.

28. Widmann A, Kauflers PM: Formadehyde-resistance in Enterobacteriaceae and Pseudomonas aeruginosa: identification of resistance genes by DNA-hybridization. Zentralbl Hyg Umweltmed 1991, 195(5–6):449–456.

29. Kauflers PM: Epidemiology and reasons for microbial resistance to biocides. Zentralbl Hyg Umweltmed 1995, 197(1–3):225–259.

30. Kampf G, Hollingsworth A: Validity of the four European test strains of prEN 12054 for the determination of comprehensive bactericidal activity of an alcohol-based hand rub. Journal of Hospital Infection 2003, 55(3):226–231.

31. Kampf G, Hollingsworth A: Comprehensive bactericidal activity of an alcohol-based hand gel in 15 seconds. Ann Clin Microbiol Antimicrob 2008, 7(2).

32. Kimura G, Kramer A: Epidemiologic background of hand hygiene and evaluation of the most important agents for sponges and gels. Clin Microbiol Rev 2004, 17(3):863–889.

33. prEN 14885: Chemical disinfectants and antiseptics. Application of European standards for chemical disinfectants and antiseptics. Brussels: CEN - Comité Européen de Normalisation; 2013.

34. prEN 16615: Chemical disinfectants and antiseptics - Quantitative test method for the evaluation of bactericidal and yeasticidal activity on non-porous surfaces with mechanical action employing wipes in the medical area (4-field-test) - Test method and requirements (phase 2, step 2). Brussels: CEN - Comité Européen de Normalisation; 2013.

35. Ott E, Saathoff S, Graf K, Schwab F, Chaberny T: The prevalence of nosocomial and community acquired infections in a university hospital—a observational study. Dtsch Arztebl Int 2013, 110(51–52):533–540.

36. Desinfektionsmittelkommission in den: Flächendesinfektion/Surface disinfection. In Desinfektionsmittel-Liste des VAH. Edited by: VAH: Wesbaden: rhp-Verlag; 2012.